Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC)
To evaluate the effectiveness and safety of anlotinib combined with TQB2450 (PD-L1 inhibitor) in the first-line treatment of patients with advanced ESCC.
Esophageal Squamous Cell Carcinoma
DRUG: Anlotinib+TQB2450
Objective Response Rate(ORR), The RECIST1.1 and iRECIST standards were used to evaluate the efficacy of drugs, with the RECIST1.1 evaluation standard as the main and the iRECIST standard as a supplement., about 2 years
Safety:adverse events, adverse events (AEs) categorized by severity in accordance with the NCI CTC AE Version 5.0, about 2 years|Progression Free Survival(PFS), about 2 years|Disease Control Rate(DCR), about 2 years|Duration of Response(DoR), about 2 years|Overall Survival(OS), about 2 years
To evaluate the effectiveness and safety of anlotinib combined with TQB2450 (PD-L1 inhibitor) in the first-line treatment of patients with advanced ESCC.